BioCryst Pharmaceuticals, Inc. (BCRX) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.99 --0%
Revenue Growth %: +13.7%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.7%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $8.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Sonoma Pharmaceuticals (SNOA) Misses Q4 EPS by 33c
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
